Loading
A Chinese case-control study of about 16,700 people building a multi-omic blood test for several cancers.
PROFOUND (NCT06217900) is an observational study sponsored by Shanghai Weihe Medical Laboratory Co., Ltd with Peking University People's Hospital. It develops and validates in a blinded set a machine-learning multi-cancer early detection model from blood multi-omic analysis.
The registry record, read on 29 October 2026, gives its status as active, not recruiting, with an estimated 16,666 participants, a start on 28 December 2023 and primary completion expected on 31 October 2026.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/